MedTrace Logo

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19

NCT04346628 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2022-07-13

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the efficacy of oral favipiravir plus standard of care treatment (SOC) compared with placebo plus SOC in reducing the duration of shedding of SARS-CoV2 virus in patients with mild or asymptomatic COVID-19.

Conditions

Interventions

DRUG

Favipiravir

Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).

DRUG

Placebo

Placebo to match favipiravir administered orally through day 10.

OTHER

Standard of care treatment

Standard of care treatment for COVID-19 infection

Sponsors & Collaborators

Principal Investigators

  • Yvonne (Bonnie) A Maldonado, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-12
Primary Completion
2021-04-16
Completion
2021-04-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04346628 on ClinicalTrials.gov